Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01050699 · ClinicalTrials.gov registry record · Phase 4
Sleep Intervention During Acute Lung Injury
A Phase 4 study, sponsored by University of Arizona.
- Completed
- Registry status
- Phase 4
- Development phase
- 90
- Enrollment target
NCT01050699 is a Phase 4 study that has completed, run by University of Arizona. The registered enrollment target is 90 participants.
The verdict
NCT01050699, a Phase 4 study, has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 90 participants
- Enrollment target
Study Summary
The central purpose of this proposal is to study the short-term effects of sedation with sympatholysis, using α2 adrenergic agent Dexmedetomidine, on sleep and inflammation in critically ill patients with Acute Lung Injury and Acute Respiratory Disorder Syndrome (ALI/ARDS). An additional objective is to determine the effect of Dexmedetomidine sedation on the in-vitro production of sleep-modulating inflammatory cytokines by peripheral blood mononuclear cells of critically ill patients with ALI/ARDS.
Interventions
- DRUG Dexmedetomidine
- DRUG Midazolam and Fentanyl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2009-08 |
| Est. Completion | 2019-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01050699
The ClinicalTrials.gov registry entry for NCT01050699 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dexmedetomidine is the first listed.
NCT01050699 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01050699 about?
NCT01050699 is a clinical study titled "Sleep Intervention During Acute Lung Injury". The central purpose of this proposal is to study the short-term effects of sedation with sympatholysis, using α2 adrenergic agent Dexmedetomidine, on sleep and inflammation in critically ill patients with Acute Lung Injury and Acute Respiratory Disorder Syndrome (ALI/ARDS). An additional objective i...
What is the current status of trial NCT01050699?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 90 participants. The study started on 2009-08. Estimated completion is 2019-01.
What interventions are being tested in trial NCT01050699?
The interventions under investigation include: Dexmedetomidine (DRUG), Midazolam and Fentanyl (DRUG).
Who is sponsoring clinical trial NCT01050699?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.